<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95573">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860638</url>
  </required_header>
  <id_info>
    <org_study_id>MO28347</org_study_id>
    <secondary_id>2012-003138-17</secondary_id>
    <nct_id>NCT01860638</nct_id>
  </id_info>
  <brief_title>A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Addition of Continuous Multiple Line Bevacizumab Treatment to Lomustine in Second (2nd)-Line Followed by Standard of Care (SOC) in Third (3rd)-Line and Beyond Compared to Addition of Placebo, Following First Progression of Disease (PD1) in Patients With Glioblastoma (GBM) After First (1st)-Line Treatment With Radiotherapy, Temozolomide and Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, double-blind, placebo-controlled, randomized study will evaluate the
      efficacy and safety of the addition of bevacizumab or placebo treatment to lomustine in
      second-line treatment and standard of care (SOC) in third-line treatment following disease
      progression after first-line treatment in participants with newly diagnosed glioblastoma.
      All enrolled participants will receive first-line treatment with radiotherapy, temozolomide
      and bevacizumab (10 milligrams per kilogram per week [mg/kg/week] intravenously [IV] every 2
      weeks). At the first disease progression (PD1), eligible participants will be randomized to
      receive lomustine plus either bevacizumab (10 mg/kg/week IV every 2 weeks) or placebo for
      2nd-line treatment. After further disease progression (PD2), participants will receive a
      standard of care agent and continued bevacizumab or placebo for 3rd-line treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival, defined as time from randomization (at PD1) to death from any cause</measure>
    <time_frame>approximately 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life: EORTC QLQ-BN20</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource utilization (EQ-5D)</measure>
    <time_frame>approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second-line progression-free survival</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Third-line progression-free survival</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates: Proportion of participants with a best overall response of complete response (CR) or partial response (PR)</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rates: Proportion of participants with a best overall response of CR, PR or stable disease</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature and severity of adverse events</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life: European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 and BN20</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function tests</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource utilization (hospitalizations, EQ-5D)</measure>
    <time_frame>approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>1st-line treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive first-line treatment with radiotherapy, temozolomide and bevacizumab (10 milligrams per kilogram per week [mg/kg/week] IV every 2 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-PD1, Bevacizumab + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lomustine plus either bevacizumab (10 mg/kg/week IV every 2 weeks) or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-PD1, Placebo + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a SOC agent and continued bevacizumab or placebo for 3rd-line treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered at a dose of 10 mg/kg IV every 2 weeks, followed by 15 mg/kg IV every 3 weeks until disease progression (PD1).</description>
    <arm_group_label>1st-line treatment</arm_group_label>
    <arm_group_label>Post-PD1, Bevacizumab + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <description>Lomustine will be administered orally at a dose of 90 milligrams per meter square (mg/m^2; may be increased to 110 mg/m^2) once every 6 weeks.</description>
    <arm_group_label>Post-PD1, Bevacizumab + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
    <arm_group_label>Post-PD1, Placebo + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Post-PD1: Bevacizumab placebo will be administered IV every 2 weeks.</description>
    <arm_group_label>Post-PD1, Bevacizumab + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
    <arm_group_label>Post-PD1, Placebo + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy wil be administered as standard first-line treatment.</description>
    <arm_group_label>1st-line treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Post-PD1: SOC agent indicated for use in 3rd- and subsequent lines of treatment at the Investigator's discretion.</description>
    <arm_group_label>Post-PD1, Bevacizumab + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
    <arm_group_label>Post-PD1, Placebo + Lomustine (2nd-line)/SOC (3rd-line)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide will be adminsistered daily at standard doses orally.</description>
    <arm_group_label>1st-line treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult participants greater than or equal to (&gt;=) 18 years of age

          -  Newly diagnosed, histologically confirmed glioblastoma not previously treated with
             chemotherapy or radiotherapy

          -  If female and not postmenopausal (less than [&lt;] 12 months of amenorrhea) or
             surgically sterile, must agree to use a highly effective contraceptive method during
             the treatment period and for at least 6 months after the last dose of study drug

          -  Karnofsky performance status (KPS) &gt;= 60

          -  Mandatory tissue collection during pre-study surgery or biopsy for confirmation of
             the diagnosis and pathology

          -  Craniotomy or intracranial biopsy site must be adequately healed. Study treatment
             should be initiated &gt; 28 days following the last surgical procedure

        Principal eligibility criteria at the time of randomization (following PD1)

          -  Documented disease progression

          -  Eligibility for 2nd-line treatment with lomustine and bevacizumab as investigational
             medicinal products

          -  Patients for whom operation or re-operation is indicated before 2nd-line treatment
             starts, tissue submission is mandatory

          -  Eastern Cooperative Oncology Group (ECOG) performance status is 0-2 when starting
             2nd-line treatment

          -  Bevacizumab was well tolerated and treatment interruption lasted not more than 60
             days

        Exclusion Criteria:

          -  Any prior chemotherapy for glioblastoma and low grade astrocytomas

          -  Any prior radiotherapy to the brain or prior radiotherapy resulting in a potential
             overlap in the radiation field

          -  Prior or current anti-angiogenic treatment

          -  Treatment with any other investigational drug within 28 days or 2 investigational
             agent half-lives (whichever is longer) prior to first study treatment

          -  Inadequate hematological, renal or liver function

          -  Inadequately controlled hypertension

          -  Prior history of gastrointestinal perforation or abscess

          -  Clinically significant cardiovascular disease, New York Heart Association (NYHA) &gt;=
             Grade II congestive heart failure, or serious cardiac arrhythmia uncontrolled by
             medication or potentially interfering with protocol treatment

          -  History or evidence of central nervous system disease unrelated to cancer unless
             adequately treated with standard medical therapy

          -  History or evidence of inherited bleeding diathesis or significant coagulopathy at
             risk of bleeding

          -  Serious non-healing wound, active ulcer, or untreated bone fracture

          -  Known hypersensitivity to any component of Avastin/placebo or any of the study drugs

          -  Active infection requiring intravenous antibiotics at start of study treatment

          -  Other malignancy within 5 years prior to study enrollment, except for carcinoma in
             situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or
             ductal carcinoma in situ treated with curative intent

          -  Pregnant or lactating women

          -  Participation in any other study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kifisia</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marousi</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linkoeping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adana</city>
        <zip>00001</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmit</city>
        <zip>31380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>N7 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M2O 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Albania</country>
    <country>Argentina</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Egypt</country>
    <country>Ireland</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Serbia</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>May 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
